Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))



    LAVAL, QC, June 21 /CNW Telbec/ - Neurochem Inc. (NASDAQ:   NRMX; TSX: NRM)
announces that it has received a third recommendation from the European Data
Safety Monitoring Board (DSMB) to continue its ongoing European Phase III
clinical trial for tramiprosate (ALZHEMED(TM)), Neurochem's investigational
product candidate for the treatment of Alzheimer's disease (AD).
    The DSMB is made up of independent clinical experts who monitor and
evaluate the safety of patients taking part in the tramiprosate (ALZHEMED(TM))
Phase III clinical trial. In Europe, this third recommendation by the DSMB
members was based on their recent review of the available safety data from
747 patients who have been on study medication for an average of 5.7 months.
    Neurochem is progressing with its multicenter, randomized, double-blind,
placebo-controlled, three-armed and parallel-designed, 18-month Phase III
clinical trial for tramiprosate (ALZHEMED(TM)) in Europe. This clinical trial
was initiated in September 2005. More than 950 mild-to-moderate AD patients at
close to 70 sites across ten European countries are already enrolled in this
clinical trial. The recruitment will continue at least until after top-line
results of the North American study are released. With respect to the
completed Phase III North American clinical trial for tramiprosate
(ALZHEMED(TM)), Neurochem received during the course of the clinical trial
five recommendations from the North American DSMB to continue the study.
    Tramiprosate (ALZHEMED(TM)) is a small, orally-administered molecule
known as an amyloid (B) antagonist, which crosses the blood-brain-barrier,
binds to soluble A(B) peptide and interferes with the amyloid cascade that is
associated with amyloid deposition and the toxic effects of A(B) peptide in
the brain.

    About Alzheimer's Disease

    AD is a leading cause of death in older people. The disease is
characterized by the progressive death of nerve cells in the brain, making it
difficult for the brain's signals to be transmitted properly. A person with AD
experiences problems with memory, judgment, thinking, and eventually with
motor functions, all of which make it difficult for the person to participate
in daily activities.
    According to the U.S. Alzheimer Association (2007), there are now more
than five million people in the United States living with Alzheimer's disease.
This number includes 4.9 million people aged 65 and older. It also includes at
least 200,000 individuals younger than 65 with early-onset Alzheimer's
disease. It is estimated that by 2010, there will be 454,000 new cases of AD a
year, 615,000 new cases by 2030 and 959,000 new cases by 2050. In the United
States, the direct and indirect costs of AD and other dementias amount to more
than US$148 billion annually.

    About Neurochem

    Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA)
amyloidosis, and is under regulatory review for marketing approval by the
U.S. Food and Drug Administration, the European Medicines Agency and
Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's
disease, has completed a Phase III clinical trial in North America and is
currently in a Phase III clinical trial in Europe, while tramiprosate
(CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral
Amyloid Angiopathy, has completed a Phase IIa clinical trial.

    To Contact Neurochem

    For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1 (877) 680-4500 or
visit our Web site at www.neurochem.com.

    This news release contains forward-looking statements regarding
tramiprosate (ALZHEMED(TM)), as well as regarding continuing and further
development efforts. These statements are based on the current analysis and
expectations of management. Drug development necessarily involves numerous
risks and uncertainties, which could cause actual results to differ materially
from this current analysis and these expectations. Analysis regarding the
results of clinical trials may not provide definitive results regarding
safety, tolerability or therapeutic benefits. There is no certainty that
regulators will ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the
public. Risks and uncertainties may include: failure to demonstrate the
safety, tolerability and efficacy of our product, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, the expense and uncertainty of obtaining regulatory approval,
including from the FDA, and the possibility of having to conduct additional
clinical trials. Further, even if regulatory approval is obtained, therapeutic
products are generally subject to: stringent on-going governmental regulation,
challenges in gaining market acceptance, and competition. Neither Neurochem
Inc., nor Neurochem (International) Limited undertake any obligation to
publicly update any forward-looking statements, whether as a result of new
information, future events, or otherwise. Please see Neurochem Inc.'s Annual
Information Form for further risk factors that might affect Neurochem Inc.,
Neurochem (International) Limited and their respective businesses.




For further information:

For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4572, lhebert@neurochem.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890